Last edition
News about "Cancer Discovery journal"
Ranok Therapeutics Reports Promising Phase 1a Results for KRAS G12D Cancer Therapy RNK08954
Ranok Therapeutics has reported positive Phase 1a clinical data for investigational KRAS G12D inhibitor RNK08954, demonstrating encouraging response rates and tolerability in advanced solid tumor patients, including those with non-small cell lung cancer.
Cancer Discovery Journal | 12/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members